MedPage Today on MSN6d
Better Response, Survival in Head and Neck Cancer With Dual Pre-Op Immunotherapy
Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...
Fierce Pharma2d
FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again
Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...
Clinical Trials Arena on MSN2d
MacroGenics axes ADC drug following Phase II failure in prostate cancer
The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.
Healio4d
AK104 with concurrent radiotherapy shows efficacy in locally advanced cervical cancer
The addition of AK104 to concurrent chemoradiotherapy improved survival outcomes for patients with locally advanced cervical ...
The Pharma Letter2d
Akeso shows promise in cervical cancer with early cadonilimab data
Chinese biotech Akeso (HKEX: 9926) has reported encouraging early data from a Phase III trial of its bispecific antibody ...
Labiotech.eu11d
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
Cancer Therapy Advisor7d
Cadonilimab-Lenvatinib Combo Exhibits Activity in Advanced Endometrial Cancer
Combination treatment with cadonilimab and lenvatinib can produce responses in patients with advanced endometrial cancer.
Healio6d
Two-drug regimen active in advanced endometrial cancer
A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...